STOCK TITAN

Verastem Inc - VSTM STOCK NEWS

Welcome to our dedicated news page for Verastem (Ticker: VSTM), a resource for investors and traders seeking the latest updates and insights on Verastem.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Verastem's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Verastem's position in the market.

Rhea-AI Summary
Verastem Oncology to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
conferences
-
Rhea-AI Summary
Verastem Oncology enters collaboration with GenFleet Therapeutics to advance three oncology discovery programs targeting RAS pathway-driven cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.67%
Tags
none
-
Rhea-AI Summary
Verastem Oncology reported positive results from the RAMP 201 trial of avutometinib and defactinib in recurrent LGSOC. They also finalized the design of the Phase 3 confirmatory trial and raised $97.8M in a public offering, bringing their total cash to $183.1M. The company aims to file for accelerated approval based on mature results from RAMP 201 and data from the FRAME trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.57%
Tags
management
-
Rhea-AI Summary
Verastem Oncology (Nasdaq:VSTM) has granted stock options to five new employees. The options allow them to purchase 28,917 shares of the company's common stock. The exercise price is $7.75 per share, and the options will vest over a period of four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.57%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.99%
Tags
offering
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.99%
Tags
offering
-
Rhea-AI Summary
Verastem Oncology announces a 1-for-12 reverse stock split of its common stock to increase per share trading price and satisfy listing requirements on Nasdaq. The split will be effective on May 31, 2023, and trading will open on June 1, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
none
Verastem Inc

Nasdaq:VSTM

VSTM Rankings

VSTM Stock Data

298.99M
13.68M
0.55%
66.79%
3.02%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Needham

About VSTM

verastem, inc. (nasdaq: vstm) is a biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells. cancer stem cells are an underlying cause of tumor recurrence and metastasis. verastem is translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer. for more information, please visit www.versatem.com